Tag: Opportunistic infection

First approved by the FDA in 1958, amphotericin B remains a critical antifungal agent, but what is the primary indication of amphotericin? It is primarily reserved for treating severe, progressive, and potentially life-threatening systemic fungal infections, particularly in immunocompromised patients.

With invasive fungal infections caused by *Scedosporium* species associated with high mortality, particularly in immunocompromised patients, determining the appropriate course of therapy is critical. Because of its complexity and the fungus's intrinsic resistance to many drugs, answering the question, 'how long is the treatment for Scedosporium?' depends heavily on specific clinical circumstances.